Disagree. Once approved the whole portfolio will be examined.
“The agreement took over two years to put together and the fact that one of the world’s most experienced dendritic cell research centers chose NWBO has major implications. One is it is a sign that the company is being de-risked as RPC would not have chosen NWBO if it thought its future was in doubt. Another is that RPC must believe that if these trials prove successful, that NWBO has the skillset to fully commercialize them. This includes both getting regulatory approval and manufacturing the therapies. RPC only makes money from these treatments via royalty payments from NWBO once sales begin. Interesting why they chose NWBO and not Merck (who RPC collaborates with in developing immunotherapies) or another big pharmaceutical.”
Include Direct and all the combination therapies it will became a platform valuation.
Market Data 
Markets 
AI
